Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
August 9, 2016 6:43 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02).
Portfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H... More